EDAP TMS SA announced that its Focal One HIFU device has been approved by Health Canada. With this approval, the company is able to market the Focal One device for the treatment of prostate cancer in Canada.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.16 USD | -0.67% |
|
+2.99% | -2.27% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.27% | 191M | |
+4.57% | 212B | |
+8.61% | 186B | |
+26.34% | 151B | |
+33.90% | 114B | |
+3.65% | 65.57B | |
+14.50% | 52.61B | |
-3.30% | 46.8B | |
-3.98% | 38.95B | |
+6.66% | 37.64B |
- Stock Market
- Equities
- EDAP Stock
- News EDAP TMS S.A.
- Health Canada Approves EDAP's Focal One HIFU Device